Search

Displaying results 1011 - 1020 of 10000 in total
  1. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    Astex Pharmaceuticals Inc under the name INQOVI®. … Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated

    Synonyms: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridineCategories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Amfenac

    go.drugbank.com/drugs/DB15911
    Investigational

    Amfenac is an arylacetic acid derivative and a non0steroidal anti-inflammatory agent.[A275203, A275208]

    Synonyms: (2-Amino-3-benzoylphenyl)acetic acid
  3. Drug

    Diquafosol

    go.drugbank.com/drugs/DB15919
    Investigational

    Categories: Heterocyclic Compounds, 1-RingProducts: DIQUAS-S ophthalmic solution 3%, DIQUAS Ophthalmic Solution 3%
  4. Drug

    Menadione bisulfite

    go.drugbank.com/drugs/DB15944
    Investigational

    Mixtures: HEMOSIN K, HEMOSIN-KCategories: Vitamin K
  5. Drug

    Strychnine

    go.drugbank.com/drugs/DB15954
    Experimental

    Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household setting
  6. Drug

    Homochlorcyclizine

    go.drugbank.com/drugs/DB15979
    Investigational

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Heterocyclic Compounds, 1-Ring
  7. Drug

    Garlic oil

    go.drugbank.com/drugs/DB15989
    Investigational

    Mixtures: Hovid Omega-3 + GarlicCategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  8. Drug

    Indocyanine green

    go.drugbank.com/drugs/DB16024
    ApprovedInvestigationalWithdrawn

    Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household setting
  9. Drug

    Plixorafenib

    go.drugbank.com/drugs/DB16038
    Investigational

    PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

  10. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates